Interleukin (IL)-4 is a key
cytokine in T-helper type 2 (Th2) immune response. We have constructed a dimeric
IL-4 molecule consisting of the murine
IL-4 and the murine Fc part of
IgG2a. We first tested the biological activity of the chimeric
protein by in vitro studies using isolated murine spleen cells. IL-4-Ig was found to downregulate LPS-induced IFN-gamma and
TNF-alpha production. The immunomodulatory potential of the fusion
protein was also analyzed in non-obese diabetic (NOD) mice, an animal model for human
type 1 diabetes. Female NOD mice aged 10 weeks were treated once with
cyclophosphamide to accelerate and synchronize the progression of insulitis. Treatment with IL-4-Ig induced strong modulation of the pancreatic
cytokine balance. Expression was downregulated for both Th1-specific
cytokine IFN-gamma and the Th2-specific
cytokine IL-10.
IL-12p40 expression was only slightly affected. Interestingly, infiltration increased in the islets of IL-4-Ig-treated animals, and therefore did not correlate with the decreased IFN-gamma expression. Hence, IL-4-Ig did not prevent the progression from peri- to intra-insulitis, but suppressed inflammatory
cytokine production. In most experiments, the biological activity of IL-4-Ig and
IL-4 was comparable. We conclude that treatment with the chimeric
protein IL-4-Ig effectively downregulates Th1 responses but simultaneously augments intra-islet infiltration.